Log In
CQMS
Make a Donation
Log In
Donate
DONATE OR FUNDRAISE
Donate
Read Roland's story about participating in a prostate cancer trial
Catch up with the news from our 2026 Annual Scientific Meeting
Read about TROG's new President-Elect and Board Members
TROG Research Excellence Award winners announced.
First participant recruited for new lung cancer trial
Secondary Data Analysis grant recipient announced

TROG 95.01 – Rectal Cancer

Completed
Gastrointestinal

A Randomised Trial Comparing Adjuvant Protracted Venous Infusion and Bolus 5FU/Leucovorin with Either Early or Late Radiotherapy in Rectal Caner

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)
Prev Post

TROG 95.02 – Proctitis – Rectal Sucralfate

Next Post

TROG 94.01/AGITG IG9401 – Oesophagus – Localised Resectable (IG9401)

Related Post

9 April, 2026

Vale Professor Jim Denham OAM, TROG founder and world-class researcher

9 April 2026 TROG Cancer Research honours the life

31 March, 2026

TROG Secondary Data Analysis Grant awarded to project to better understand prostate cancer therapy outcomes

LATEST NEWS: 31 March 2026 TROG’s inaugural Secondary Data